| Patent application number | Description | Published |
|---|
| 20130108710 | Antimalarial Drug Which Contains 5-Aminolevulinic Acid or Derivative Thereof as Active Ingredient | 05-02-2013 |
| 20130158293 | CANCER HEAT THERAPY-ENHANCING AGENT - Provided is an enhancer for cancer thermotherapy not combined with photodynamic therapy. Cancer treatment not combined with photodynamic therapy is made available by using, as an enhancer for cancer thermotherapy, 5-aminolevulinic acids represented by formula (1): | 06-20-2013 |
| 20140256806 | PROPHYLACTIC AGENT FOR CHRONIC KIDNEY DISEASE - A method for ameliorating and/or preventing chronic kidney disease includes administering to a subject in need thereof an agent containing 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt thereof as an active ingredient. Preferably, these ALAs contain a metal-containing compound, such as sodium ferrous citrate. The above-mentioned ALAs, ALA; various esters, such as ALA methylester, ALA ethylester, ALA propylester, ALA butylester, and ALA pentylester; and hydrochlorides, phosphates, and sulfates, and the like of these ALA esters are preferred examples. | 09-11-2014 |
| 20140288172 | ERYTHROPOIETIN PRODUCTION-PROMOTING AGENT - A therapeutic and/or prophylactic agent for renal anemia comprising ALAs and an erythropoietin production promoter comprising ALAs. | 09-25-2014 |
| 20140288173 | ANEMIA OF CANCER IMPROVING/PROPHYLACTIC AGENT - A method for ameliorating and/or preventing cancerous anemia includes administering to a subject in need thereof an agent containing 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt thereof. Preferably, these ALAs contain a metal-containing compound, such as sodium ferrous citrate. The above-mentioned ALAs, ALA; various esters such as ALA methylester, ALA ethylester, ALA propylester, ALA butylester, and ALA pentylester; and hydrochlorides, phosphates, and sulfates, and the like of these ALA esters are preferred examples. | 09-25-2014 |
| 20140302173 | TREATMENT AGENT AND/OR PROPHYLACTIC AGENT FOR SIDE EFFECTS OF CANCER DRUGS - A method for treating side effects of anticancer agent includes administering to a subject in need thereof a prophylactic and/or therapeutic agent containing a therapeutically effective amount of a compound shown by the following Formula (1): | 10-09-2014 |
| 20140343140 | Agent for Preventing and/or Treating Veisalgia - [Problem] To provide an agent for preventing and/or treating veisalgia. [Solution] Provided is an agent for preventing and/or treating veisalgia, the agent including an ALA (5-aminolevulinic acid). | 11-20-2014 |
| 20150038837 | DEVICE FOR DETERMINING METASTASIS OF CANCER TO SENTINEL LYMPH NODE - Provided is a device capable of determining whether or not cancer has metastasized to a sentinel lymph node, such as the axillary lymph node, thickly covered with fat, safely and in a simple manner without confirmation by biopsy or extirpation. Fluorescence generated in a sentinel lymph node upon the excitation of protoporphyrin (a photosensitizing substance) derived from 5-ALA administered to a subject can be detected by passing a hollow tube, into which a small-diameter optical fiber for launching light and the small-diameter optical fiber for receiving light are inserted, through the lymph vessel to identify the presence or absence of the metastasis of cancer cells even before the surgery of cancer or during prognosis. | 02-05-2015 |
| Patent application number | Description | Published |
|---|
| 20140186464 | PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR SEPSIS - The present invention provides a sepsis therapeutic drug useful for prophylaxis and treatment of sepsis. A prophylactic agent and/or a therapeutic agent for sepsis containing 5-aminolevulinic acid (5-ALA) or a derivative thereof or a pharmacologically acceptable salt of 5-ALA or the derivative as an active ingredient is prepared. The prophylactic agent and/or the therapeutic agent preferably contains a metal-containing compound such as ferrous sodium citrate in addition to the ALAs. Preferred examples of the ALAs include ALA; various esters of ALA such as methyl, ethyl, propyl, butyl, and pentyl esters; and hydrochlorides, phosphates, sulfates of ALA and the esters. | 07-03-2014 |
| 20140249217 | ENHANCER OF SURVIVAL OF TRANSPLANTED ORGAN - The present invention provides an agent for promoting graft survival which can suppress rejection without use of existing immunosuppressants, an organ preservation solution capable of maintaining the freshness of an organ excised from a donor, and the like. An agent for promoting graft survival or an organ preservation solution is prepared, which comprises 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of ALA or the derivative and an iron compound as active ingredients. Preferable examples of the ALAs can include ALA and various esters such as methyl ester, ethyl ester, propyl ester, butyl ester, and pentyl ester of ALA, and their hydrochlorides, phosphates, and sulfates. Preferable examples of the iron compound can include sodium ferrous citrate. | 09-04-2014 |
| 20150031013 | DIAGNOSTIC AGENT FOR TUMOR - It is to provide a tumor diagnostic agent and a tumor determination method enabling not only determination of the presence or absence of a tumor in a subject, but also determination of whether the tumor is a malignant tumor or a benign tumor, which can be used simply at low cost with reduced side effects and burden. 5-aminolevulinic acid (ALA) or its derivative, or a salt thereof is orally administered at a dose of 5 to 7 mg in terms of ALA per kg of body weight, and a urine sample 4 to 12 hours after the administration is collected. Porphyrins and creatinine in the urine sample are quantitated, and based on the value (nmol/gCre) obtained by dividing the amount of porphyrins by the amount of creatinine, a distinction among an individual without a tumor, an individual with a benign tumor, and an individual with a malignant tumor is determined. The presence or absence of a malignant tumor in a subject can be clearly determined by administering 1 to 3 mg of ALAs in terms of ALA per kg of body weight. | 01-29-2015 |
